Bioptimus
Paris AI company training universal, multimodal foundation models of biology across molecule, cell, tissue and organ scales; its H-Optimus pathology model and M-Optimus model, which integrates histology with spatial transcriptomics and genomics, power drug-target discovery, biomarker work and treatment-response prediction for pharma R&D.
Headquarters
Paris, France
Year Founded
2024
Founders
Jean-Philippe Vert (CEO), Zelda Mariet, Felipe Llinares-Lopez
Country
France
Financial Information
Funding Stage
Series A
Recent Funding
$76M
Funding By
Cathay Innovation, Sofinnova Partners, Bpifrance Large Venture, Andera Partners, Hitachi Ventures
Core Technology
Multimodal foundation models spanning molecule-to-organ biology (H-Optimus, M-Optimus)
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Used by 16 of the top 20 pharma companies (per company)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Foundation models that learn across molecular, cellular and tissue scales rather than a single modality